{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T10:13:46Z","timestamp":1793787226080,"version":"4.6.1"},"reference-count":120,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.critrevonc.2019.102831","type":"journal-article","created":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T11:46:27Z","timestamp":1573645587000},"page":"102831","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":150,"special_numbering":"C","title":["Prevention of chemotherapy-induced peripheral neuropathy: A review of recent findings"],"prefix":"10.1016","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7445-6540","authenticated-orcid":false,"given":"Eiman Y.","family":"Ibrahim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9657-9704","authenticated-orcid":false,"given":"Barbara E.","family":"Ehrlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.critrevonc.2019.102831_bib0005","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1158\/1055-9965.EPI-10-0437","article-title":"Global patterns of cancer incidence and mortality rates and trends","volume":"19","author":"Jemal","year":"2010","journal-title":"Cancer Epidemiol. Prevent. Biomark."},{"key":"10.1016\/j.critrevonc.2019.102831_bib0010","article-title":"Taxanes for adjuvant treatment of early breast cancer","volume":"4","author":"Ferguson","year":"2007","journal-title":"Cochrane Database Syst. Rev."},{"issue":"3","key":"10.1016\/j.critrevonc.2019.102831_bib0015","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.critrevonc.2008.01.008","article-title":"Peripheral nerve damage associated with administration of taxanes in patients with cancer","volume":"66","author":"Argyriou","year":"2008","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2019.102831_bib0020","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.neulet.2014.10.014","article-title":"Chemotherapy-induced peripheral neuropathy: what do we know about mechanisms?","volume":"596","author":"Carozzi","year":"2015","journal-title":"Neurosci. Lett."},{"issue":"29","key":"10.1016\/j.critrevonc.2019.102831_bib0025","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.2174\/092986708786848569","article-title":"Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies","volume":"15","author":"Park","year":"2008","journal-title":"Curr. Med. Chem."},{"issue":"1-3","key":"10.1016\/j.critrevonc.2019.102831_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tox.2011.10.019","article-title":"Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy","volume":"291","author":"Jaggi","year":"2012","journal-title":"Toxicology."},{"key":"10.1016\/j.critrevonc.2019.102831_bib0035","article-title":"Healthcare costs and workloss burden of patients with chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer","volume":"2012","author":"Pike","year":"2012","journal-title":"Chemother. Res. Pract."},{"issue":"6","key":"10.1016\/j.critrevonc.2019.102831_bib0040","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/jnci\/djz011","article-title":"The National Cancer Institute Clinical Trials Planning Meeting for Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy","volume":"111","author":"Dorsey","year":"2019","journal-title":"JNCI"},{"issue":"8","key":"10.1016\/j.critrevonc.2019.102831_bib0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0221787","article-title":"A systematic summary and comparison of animal models for chemotherapy induced (peripheral) neuropathy (CIPN)","volume":"14","author":"Gadgil","year":"2019","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.critrevonc.2019.102831_bib0050","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejca.2005.06.030","article-title":"Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes","volume":"42","author":"Mielke","year":"2006","journal-title":"Eur. J. Cancer"},{"issue":"12","key":"10.1016\/j.critrevonc.2019.102831_bib0055","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","article-title":"Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis","volume":"155","author":"Seretny","year":"2014","journal-title":"Pain."},{"issue":"30","key":"10.1016\/j.critrevonc.2019.102831_bib0060","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1200\/JCO.2014.58.8533","article-title":"Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance)","volume":"33","author":"Pachman","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2019.102831_bib0065","doi-asserted-by":"crossref","first-page":"72","DOI":"10.4103\/1673-5374.198986","article-title":"Challenges and opportunities identifying therapeutic targets for chemotherapy-induced peripheral neuropathy resulting from oxidative DNA damage","volume":"12","author":"Kelley","year":"2017","journal-title":"Neural Regen. Res."},{"issue":"7","key":"10.1016\/j.critrevonc.2019.102831_bib0070","first-page":"2241","article-title":"Incidence of taxane-induced peripheral neuropathy receiving treatment and prescription patterns in patients with breast","volume":"25","author":"Song","year":"2017","journal-title":"cancer"},{"issue":"18","key":"10.1016\/j.critrevonc.2019.102831_bib0075","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2013.54.0914","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: american Society of Clinical Oncology clinical practice guideline","volume":"32","author":"Hershman","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2019.102831_bib0080","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s00520-015-3063-4","article-title":"National Cancer Institute-supported chemotherapy-induced peripheral neuropathy trials: outcomes and lessons","volume":"24","author":"Majithia","year":"2016","journal-title":"Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer."},{"issue":"1","key":"10.1016\/j.critrevonc.2019.102831_bib0085","first-page":"Cd005228","article-title":"Interventions for preventing neuropathy caused by cisplatin and related compounds","author":"Albers","year":"2007","journal-title":"Cochrane Database Syst. Rev."},{"issue":"7","key":"10.1016\/j.critrevonc.2019.102831_bib0090","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1001\/jamaneurol.2016.0383","article-title":"The association of chemotherapy-induced peripheral neuropathy symptoms and the risk of falling","volume":"73","author":"Kolb","year":"2016","journal-title":"JAMA Neurol."},{"issue":"11","key":"10.1016\/j.critrevonc.2019.102831_bib0095","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.1007\/s00520-016-3329-5","article-title":"Evaluating the impact of chemotherapy-induced peripheral neuropathy symptoms (CIPN-sx) on perceived ability to work in breast cancer survivors during the first year post-treatment","volume":"24","author":"Zanville","year":"2016","journal-title":"Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer."},{"key":"10.1016\/j.critrevonc.2019.102831_bib0100","volume":"48","author":"Albers","year":"2019"},{"issue":"11","key":"10.1016\/j.critrevonc.2019.102831_bib0105","first-page":"3485","article-title":"Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey","volume":"25","author":"McCrary","year":"2017","journal-title":"Support. Care Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2019.102831_bib0110","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.critrevonc.2011.04.012","article-title":"Chemotherapy-induced peripheral neurotoxicity (CIPN): an update","volume":"82","author":"Argyriou","year":"2012","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"4","key":"10.1016\/j.critrevonc.2019.102831_bib0115","first-page":"201","article-title":"Pilot testing a web-based system for the assessment and management of chemotherapy-induced peripheral neuropathy","volume":"35","author":"Knoerl","year":"2017","journal-title":"Comput. Inform. Nurs."},{"issue":"7","key":"10.1016\/j.critrevonc.2019.102831_bib0120","first-page":"322","article-title":"Usability and acceptability of a web-based program for chemotherapy-induced peripheral neuropathy","volume":"34","author":"Tofthagen","year":"2016","journal-title":"Comput. Inform. Nurs."},{"issue":"2","key":"10.1016\/j.critrevonc.2019.102831_bib0125","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/annonc\/mds329","article-title":"The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings","volume":"24","author":"Cavaletti","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2019.102831_bib0130","series-title":"Management of Side Effects in the Personalized Medicine Era: Chemotherapy-induced Peripheral Neuropathy. Pharmacogenomics in Drug Discovery and Development","first-page":"301","author":"Alberti","year":"2014"},{"issue":"18","key":"10.1016\/j.critrevonc.2019.102831_bib0135","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2013.54.0914","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: american Society of Clinical Oncology clinical practice guideline","volume":"32","author":"Hershman","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2019.102831_bib0140","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2217\/pmt-2018-0020","article-title":"An updated understanding of the mechanisms involved in chemotherapy-induced neuropathy","volume":"8","author":"Boyette-Davis","year":"2018","journal-title":"Pain Manag."},{"issue":"15","key":"10.1016\/j.critrevonc.2019.102831_bib0145","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1056\/NEJM199504133321507","article-title":"Paclitaxel (taxol)","volume":"332","author":"Rowinsky","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.102831_bib0150","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.expneurol.2016.11.015","article-title":"Neurotoxic mechanisms of paclitaxel are local to the distal axon and independent of transport defects","volume":"288","author":"Gornstein","year":"2017","journal-title":"Exp. Neurol."},{"issue":"61","key":"10.1016\/j.critrevonc.2019.102831_bib0155","article-title":"The prophylactic effects of a traditional Japanese medicine, goshajinkigan, on paclitaxel-induced peripheral neuropathy and its mechanism of action","volume":"10","author":"Matsumura","year":"2014","journal-title":"Mol. Pain"},{"issue":"2","key":"10.1016\/j.critrevonc.2019.102831_bib0160","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.expneurol.2011.08.016","article-title":"Functional deficits in peripheral nerve mitochondria in rats with paclitaxel- and oxaliplatin-evoked painful peripheral neuropathy","volume":"232","author":"Zheng","year":"2011","journal-title":"Exp. Neurol."},{"issue":"48","key":"10.1016\/j.critrevonc.2019.102831_bib0165","doi-asserted-by":"crossref","first-page":"18356","DOI":"10.1073\/pnas.0607240103","article-title":"Paclitaxel induces calcium oscillations via an inositol 1, 4, 5-trisphosphate receptor and neuronal calcium sensor 1-dependent mechanism","volume":"103","author":"Boehmerle","year":"2006","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"11 Pt B","key":"10.1016\/j.critrevonc.2019.102831_bib0170","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/j.bbamcr.2018.05.005","article-title":"NCS-1 is a regulator of calcium signaling in health and disease","volume":"1865","author":"Boeckel","year":"2018","journal-title":"Biochim. et biophys. acta Mol. Cell Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2019.102831_bib0175","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1172\/JCI22466","article-title":"Neuronal calcium sensor-1 enhancement of InsP3 receptor activity is inhibited by therapeutic levels of lithium","volume":"116","author":"Schlecker","year":"2006","journal-title":"J. Clin. Invest."},{"issue":"40","key":"10.1016\/j.critrevonc.2019.102831_bib0180","doi-asserted-by":"crossref","first-page":"34575","DOI":"10.1074\/jbc.M111.265751","article-title":"Protection of neuronal calcium sensor 1 protein in cells treated with paclitaxel","volume":"286","author":"Benbow","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"26","key":"10.1016\/j.critrevonc.2019.102831_bib0185","doi-asserted-by":"crossref","first-page":"11103","DOI":"10.1073\/pnas.0701546104","article-title":"Chronic exposure to paclitaxel diminishes phosphoinositide signaling by calpain-mediated neuronal calcium sensor-1 degradation","volume":"104","author":"Boehmerle","year":"2007","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"16","key":"10.1016\/j.critrevonc.2019.102831_bib0190","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1158\/1078-0432.CCR-12-0761","article-title":"Influence of polymorphic OATP1B-Type carriers on the disposition of Docetaxel","volume":"18","author":"de Graan","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.critrevonc.2019.102831_bib0195","doi-asserted-by":"crossref","first-page":"815","DOI":"10.4161\/cbt.4.8.1867","article-title":"Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel","volume":"4","author":"Smith","year":"2005","journal-title":"Cancer Biol. Ther."},{"issue":"2","key":"10.1016\/j.critrevonc.2019.102831_bib0200","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1172\/JCI96160","article-title":"OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity","volume":"128","author":"Leblanc","year":"2018","journal-title":"J. Clin. Invest."},{"issue":"11","key":"10.1016\/j.critrevonc.2019.102831_bib0205","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1096\/fj.12-214643","article-title":"Prevention of paclitaxel-induced peripheral neuropathy by lithium pretreatment","volume":"26","author":"Mo","year":"2012","journal-title":"FASEB J."},{"issue":"3","key":"10.1016\/j.critrevonc.2019.102831_bib0210","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1517\/14740338.2011.543417","article-title":"Chemotherapy-induced peripheral neuropathies: from clinical relevance to preclinical evidence","volume":"10","author":"Balayssac","year":"2011","journal-title":"Expert Opin. Drug Saf."},{"issue":"2","key":"10.1016\/j.critrevonc.2019.102831_bib0215","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2174\/157015906776359568","article-title":"Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives","volume":"4","author":"Scripture","year":"2006","journal-title":"Curr. Neuropharmacol."},{"issue":"10","key":"10.1016\/j.critrevonc.2019.102831_bib0220","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1200\/JCO.2007.11.6699","volume":"26","author":"Seidman","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2019.102831_bib0225","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ctrv.2009.10.006","article-title":"Overall survival benefit for weekly vs. Three-weekly taxanes regimens in advanced breast cancer: a meta-analysis","volume":"36","author":"Mauri","year":"2010","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.critrevonc.2019.102831_bib0230","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40880-017-0196-5","article-title":"Weekly taxane\u2013anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial","volume":"36","author":"Tan","year":"2017","journal-title":"Chin. J. Cancer"},{"key":"10.1016\/j.critrevonc.2019.102831_bib0235","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.18_suppl.cra1008","article-title":"S0221: comparison of two schedules of paclitaxel as adjuvant therapy for breast cancer","author":"Budd","year":"2013","journal-title":"Am. Soc. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2019.102831_bib0240","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1093\/annonc\/mdt018","article-title":"CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel\u2020","volume":"24","author":"Hertz","year":"2013","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2019.102831_bib0245","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/00008571-200110000-00006","article-title":"Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid","volume":"11","author":"Dai","year":"2001","journal-title":"Pharmacogenetics"},{"issue":"9","key":"10.1016\/j.critrevonc.2019.102831_bib0250","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.2217\/pgs.09.82","article-title":"Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies","volume":"10","author":"Daily","year":"2009","journal-title":"Pharmacogenomics"},{"issue":"2","key":"10.1016\/j.critrevonc.2019.102831_bib0255","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1742-7843.2008.00351.x","article-title":"Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer","volume":"104","author":"Green","year":"2009","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"2","key":"10.1016\/j.critrevonc.2019.102831_bib0260","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s10549-010-1034-5","article-title":"Association of CYP1B1 with hypersensitivity induced by taxane therapy in breast cancer patients","volume":"124","author":"Rizzo","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"issue":"7","key":"10.1016\/j.critrevonc.2019.102831_bib0265","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00228-011-1007-6","article-title":"Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer","volume":"67","author":"Bergmann","year":"2011","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"12","key":"10.1016\/j.critrevonc.2019.102831_bib0270","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S1470-2045(11)70131-0","article-title":"Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics","volume":"12","author":"Cavaletti","year":"2011","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2019.102831_bib0275","first-page":"1231","article-title":"Vinca alkaloids","volume":"4","author":"Moudi","year":"2013","journal-title":"Int. J. Prev. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2019.102831_bib0280","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev.cellbio.16.1.89","article-title":"Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics","volume":"16","author":"Downing","year":"2000","journal-title":"Annu. Rev. Cell Dev. Biol."},{"issue":"7","key":"10.1016\/j.critrevonc.2019.102831_bib0285","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.ctrv.2014.04.004","article-title":"Chemotherapy-induced neuropathy: a comprehensive survey","volume":"40","author":"Miltenburg","year":"2014","journal-title":"Cancer Treat. Rev."},{"issue":"2","key":"10.1016\/j.critrevonc.2019.102831_bib0290","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3390\/toxics3020198","article-title":"Mitochondrial dysfunction in chemotherapy-induced peripheral neuropathy (CIPN)","volume":"3","author":"Canta","year":"2015","journal-title":"Toxics."},{"issue":"45","key":"10.1016\/j.critrevonc.2019.102831_bib0295","doi-asserted-by":"crossref","first-page":"37907","DOI":"10.1074\/jbc.M112.385070","article-title":"Inhibition of paclitaxel-induced decreases in calcium signaling","volume":"287","author":"Benbow","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.critrevonc.2019.102831_bib0300","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26677","article-title":"Vincristine-induced neuropathy in pediatric patients with acute lymphoblastic leukemia in Oman: frequent autonomic and more severe cranial nerve involvement","volume":"64","author":"Nazir","year":"2017","journal-title":"Pediatr. Blood Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2019.102831_bib0305","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jfo.2013.03.007","article-title":"[Vincristine-induced unilateral ptosis: case report and review of the literature]","volume":"36","author":"Batta","year":"2013","journal-title":"J. Fr. Ophtalmol."},{"key":"10.1016\/j.critrevonc.2019.102831_bib0310","first-page":"56","article-title":"Vincristine induced cranial neuropathy","volume":"60","author":"Dixit","year":"2012","journal-title":"J. Assoc. Physicians India"},{"key":"10.1016\/j.critrevonc.2019.102831_bib0315","doi-asserted-by":"crossref","first-page":"174-","DOI":"10.3389\/fnmol.2017.00174","article-title":"Pathophysiology of chemotherapy-induced peripheral neuropathy","volume":"10","author":"Starobova","year":"2017","journal-title":"Front. Mol. Neurosci."},{"issue":"6","key":"10.1016\/j.critrevonc.2019.102831_bib0320","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/ana.24951","article-title":"Chemotherapy-induced peripheral neuropathy: a current review","volume":"81","author":"Staff","year":"2017","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.critrevonc.2019.102831_bib0325","series-title":"IASLC Thoracic Oncology","first-page":"512","article-title":"51 - adjuvant and neoadjuvant chemotherapy for early-stage nonsmall cell lung cancer","author":"Scagliotti","year":"2018"},{"issue":"481","key":"10.1016\/j.critrevonc.2019.102831_bib0330","article-title":"A mechanistic understanding of axon degeneration in chemotherapy-induced peripheral neuropathy","volume":"11","author":"Fukuda","year":"2017","journal-title":"Front. Neurosci."},{"issue":"12","key":"10.1016\/j.critrevonc.2019.102831_bib0335","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1038\/sj.bjc.6601012","article-title":"Paclitaxel induces nucleolar enlargement in dorsal root ganglion neurons in vivo reducing oxaliplatin toxicity","volume":"88","author":"Jamieson","year":"2003","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2019.102831_bib0340","doi-asserted-by":"crossref","first-page":"329","DOI":"10.5306\/wjco.v8.i4.329","article-title":"Platinum-induced neurotoxicity: a review of possible mechanisms","volume":"8","author":"Kanat","year":"2017","journal-title":"World J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.102831_bib0345","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/B978-0-444-53502-3.00031-8","article-title":"Neurological complications of chemotherapy to the central nervous system","volume":"105","author":"Newton","year":"2012","journal-title":"Handb. Clin. Neurol."},{"issue":"4","key":"10.1016\/j.critrevonc.2019.102831_bib0350","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2165\/00002018-199513040-00003","article-title":"Comparative adverse effect profiles of platinum drugs","volume":"13","author":"McKeage","year":"1995","journal-title":"Drug Saf."},{"issue":"1","key":"10.1016\/j.critrevonc.2019.102831_bib0355","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1158\/1535-7163.MCT-08-0840","article-title":"Platinum neurotoxicity pharmacogenetics","volume":"8","author":"McWhinney","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2019.102831_bib0360","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nrclinonc.2009.128","article-title":"Neurological adverse effects caused by cytotoxic and targeted therapies","volume":"6","author":"Schiff","year":"2009","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2019.102831_bib0365","first-page":"18","article-title":"Chemotherapy-induced neurotoxicity: the value of neuroprotective strategies","volume":"70","author":"Beijers","year":"2012","journal-title":"Neth. J. Med."},{"issue":"11","key":"10.1016\/j.critrevonc.2019.102831_bib0370","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S1470-2045(10)70206-0","article-title":"Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65\/GMMG-HD4 trial","volume":"11","author":"Broyl","year":"2010","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2019.102831_bib0375","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1158\/1078-0432.CCR-03-0561","article-title":"Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors","volume":"10","author":"Pei","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.critrevonc.2019.102831_bib0380","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-10-1950","article-title":"Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events","volume":"17","author":"Arastu-Kapur","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"16","key":"10.1016\/j.critrevonc.2019.102831_bib0385","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1002\/glia.21065","article-title":"Pathological adaptive responses of Schwann cells to endoplasmic reticulum stress in bortezomib-induced peripheral neuropathy","volume":"58","author":"Shin","year":"2010","journal-title":"Glia."},{"issue":"1-2","key":"10.1016\/j.critrevonc.2019.102831_bib0390","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jns.2007.05.023","article-title":"A high-dose bortezomib neuropathy with sensory ataxia and myelin involvement","volume":"263","author":"Filosto","year":"2007","journal-title":"J. Neurol. Sci."},{"issue":"5","key":"10.1016\/j.critrevonc.2019.102831_bib0395","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.102831_bib0400","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","article-title":"Proteasome inhibitors in cancer therapy","volume":"14","author":"Manasanch","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2019.102831_bib0405","doi-asserted-by":"crossref","first-page":"e72995-e","DOI":"10.1371\/journal.pone.0072995","article-title":"Bortezomib-induced painful peripheral neuropathy: an electrophysiological, behavioral, morphological and mechanistic study in the mouse","volume":"8","author":"Carozzi","year":"2013","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.critrevonc.2019.102831_bib0410","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/j.1365-2141.2005.05914.x","article-title":"A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma","volume":"132","author":"Glasmacher","year":"2006","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2019.102831_bib0415","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/CCO.0000000000000349","article-title":"Treatment and surveillance of advanced, metastatic iodine-resistant differentiated thyroid cancer","volume":"29","author":"Ibrahim","year":"2017","journal-title":"Curr. Opin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2019.102831_bib0420","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1756-8722-2-36","article-title":"Mechanism of action of lenalidomide in hematological malignancies","volume":"2","author":"Kotla","year":"2009","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2019.102831_bib0425","doi-asserted-by":"crossref","first-page":"683","DOI":"10.3109\/10428194.2012.728597","article-title":"Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma","volume":"54","author":"Zhu","year":"2013","journal-title":"Leukemia Lymphoma"},{"issue":"7","key":"10.1016\/j.critrevonc.2019.102831_bib0430","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.exphem.2014.03.005","article-title":"Immunomodulatory drugs thalidomide and lenalidomide affect osteoblast differentiation of human bone marrow stromal cells in vitro","volume":"42","author":"Bolomsky","year":"2014","journal-title":"Exp. Hematol."},{"issue":"2","key":"10.1016\/j.critrevonc.2019.102831_bib0435","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s11060-014-1632-x","article-title":"Chemotherapy-induced peripheral neuropathies in hematological malignancies","volume":"121","author":"Jongen","year":"2015","journal-title":"J. Neurooncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2019.102831_bib0440","first-page":"1622","article-title":"The dihydroxy metabolite of the teratogen thalidomide causes oxidative DNA","volume":"30","author":"Wani","year":"2017","journal-title":"Damage"},{"issue":"1","key":"10.1016\/j.critrevonc.2019.102831_bib0445","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/archderm.1994.01690010070009","article-title":"Thalidomide neuropathy incidence and clinicoelectrophysiologic findings in 42 patients","volume":"130","author":"Ochonisky","year":"1994","journal-title":"JAMA Dermatol."},{"issue":"7","key":"10.1016\/j.critrevonc.2019.102831_bib0450","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1182\/blood-2009-08-239046","article-title":"Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients","volume":"115","author":"Gay","year":"2010","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.critrevonc.2019.102831_bib0455","first-page":"Cd005454","article-title":"Antidepressants for neuropathic pain","author":"Saarto","year":"2007","journal-title":"Cochrane Database Syst. Rev."},{"issue":"6","key":"10.1016\/j.critrevonc.2019.102831_bib0460","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/mus.22092","article-title":"Evidence-based guideline: treatment of painful diabetic neuropathy--report of the American Association of Neuromuscular and Electrodiagnostic Medicine, the American Academy of Neurology, and the American Academy of Physical Medicine & Rehabilitation","volume":"43","author":"Bril","year":"2011","journal-title":"Muscle Nerve"},{"issue":"13","key":"10.1016\/j.critrevonc.2019.102831_bib0465","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2013.2813","article-title":"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial","volume":"309","author":"Smith","year":"2013","journal-title":"JAMA."},{"issue":"13","key":"10.1016\/j.critrevonc.2019.102831_bib0470","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2013.2813","article-title":"Alliance for Clinical Trials in O. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial","volume":"309","author":"Smith","year":"2013","journal-title":"JAMA."},{"issue":"5","key":"10.1016\/j.critrevonc.2019.102831_bib0475","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1007\/s10147-015-0810-y","article-title":"Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy: a pilot randomized trial","volume":"20","author":"Hirayama","year":"2015","journal-title":"Int. J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2019.102831_bib0480","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s12272-013-0057-y","article-title":"Implications and mechanism of action of gabapentin in neuropathic pain","volume":"36","author":"Kukkar","year":"2013","journal-title":"Arch. Pharm. Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2019.102831_bib0485","doi-asserted-by":"crossref","first-page":"200","DOI":"10.5603\/GP.a2018.0034","article-title":"Effectiveness of gabapentin pharmacotherapy in chemotherapy-induced peripheral neuropathy","volume":"89","author":"Magnowska","year":"2018","journal-title":"Ginekol. Pol."},{"issue":"5","key":"10.1016\/j.critrevonc.2019.102831_bib0490","first-page":"e448","article-title":"Efficacy and safety of oxycodone\/naloxone as add-on therapy to gabapentin or pregabalin for the management of chemotherapy-induced peripheral neuropathy in Korea","volume":"14","author":"Kim","year":"2018","journal-title":"Asia. J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2019.102831_bib0495","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1177\/1049909111412539","article-title":"A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study","volume":"29","author":"Mishra","year":"2012","journal-title":"Am. J. Hosp. Palliat. Care"},{"issue":"10","key":"10.1016\/j.critrevonc.2019.102831_bib0500","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1634\/theoncologist.2017-0235","article-title":"Pregabalin for the prevention of oxaliplatin-induced painful neuropathy: a randomized, double-blind trial","volume":"22","author":"de Andrade","year":"2017","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.critrevonc.2019.102831_bib0505","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2174\/1570159X15666170915143217","article-title":"Prevention and treatment for chemotherapy-induced peripheral neuropathy: therapies based on CIPN mechanisms","volume":"17","author":"Hu","year":"2019","journal-title":"Curr. Neuropharmacol."},{"issue":"9","key":"10.1016\/j.critrevonc.2019.102831_bib0510","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1002\/cncr.23008","article-title":"Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3)","volume":"110","author":"Rao","year":"2007","journal-title":"Cancer."},{"issue":"suppl 1","key":"10.1016\/j.critrevonc.2019.102831_bib0515","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000143223","article-title":"Controlled-release oxycodone in the treatment of neuropathic pain of nonmalignant and malignant causes","volume":"74","author":"Ong","year":"2008","journal-title":"Oncology."},{"issue":"11","key":"10.1016\/j.critrevonc.2019.102831_bib0520","first-page":"1020","article-title":"New practical approaches to chemotherapy-induced neuropathic pain: prevention, assessment, and treatment","volume":"30","author":"Majithia","year":"2016","journal-title":"Oncology (Williston Park, N.Y.)"},{"key":"10.1016\/j.critrevonc.2019.102831_bib0525","article-title":"Intravenous lidocaine: old-school drug, new purpose-reduction of intractable pain in patients with chemotherapy induced peripheral","volume":"2017","author":"van den Heuvel","year":"2017","journal-title":"Neuropathy"},{"issue":"6","key":"10.1016\/j.critrevonc.2019.102831_bib0530","first-page":"833","article-title":"A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA","volume":"19","author":"Barton","year":"2011","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.critrevonc.2019.102831_bib0535","first-page":"1","article-title":"Management of peripheral neuropathy induced by chemotherapy","volume":"26","author":"Maayan","year":"2019","journal-title":"Curr. Med. Chem."},{"issue":"10","key":"10.1016\/j.critrevonc.2019.102831_bib0540","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1002\/phar.1642","article-title":"Peripherally restricted cannabinoids for the treatment of pain","volume":"35","author":"Romero-Sandoval","year":"2015","journal-title":"Pharmacotherapy."},{"issue":"5","key":"10.1016\/j.critrevonc.2019.102831_bib0545","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/CAD.0b013e32832a2dc1","article-title":"Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity","volume":"20","author":"Milla","year":"2009","journal-title":"Anticancer Drugs"},{"issue":"1","key":"10.1016\/j.critrevonc.2019.102831_bib0550","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/07357909209032783","article-title":"Hexamethylmelamine and low or moderate dose cisplatin with or without pyridoxine for treatment of advanced ovarian carcinoma: a study of the Eastern Cooperative Oncology Group","volume":"10","author":"Wiernik","year":"1992","journal-title":"Cancer Invest."},{"issue":"1","key":"10.1016\/j.critrevonc.2019.102831_bib0555","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1186\/1471-2407-12-355","article-title":"Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: a randomized double-blind placebo controlled trial","volume":"12","author":"Ghoreishi","year":"2012","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2019.102831_bib0560","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/030089160509100206","article-title":"A pilot study on the effect of acetyl-L-carnitine in paclitaxel-and cisplatin-induced peripheral neuropathy","volume":"91","author":"Maestri","year":"2005","journal-title":"Tumori."},{"issue":"1","key":"10.1016\/j.critrevonc.2019.102831_bib0565","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1073\/pnas.232693499","article-title":"Up-regulation of neuronal calcium sensor-1 (NCS-1) in the prefrontal cortex of schizophrenic and bipolar patients","volume":"100","author":"Koh","year":"2003","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"9","key":"10.1016\/j.critrevonc.2019.102831_bib0570","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1158\/1055-9965.EPI-18-0167","article-title":"Hepatocellular carcinoma outcome is predicted by expression of neuronal calcium sensor 1","volume":"27","author":"Schuette","year":"2018","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.critrevonc.2019.102831_bib0575","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41523-018-0057-7","article-title":"An assessment of neuronal calcium sensor-1 and response to neoadjuvant chemotherapy in breast cancer patients","volume":"4","author":"Moore","year":"2018","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.critrevonc.2019.102831_bib0580","doi-asserted-by":"crossref","first-page":"296-","DOI":"10.3389\/fonc.2019.00296","article-title":"Systems biology understanding of the effects of Lithium on Cancer","volume":"9","author":"Ge","year":"2019","journal-title":"Front. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2019.102831_bib0585","doi-asserted-by":"crossref","first-page":"7322","DOI":"10.18632\/oncotarget.23467","article-title":"The prevention of chemotherapy induced peripheral neuropathy by concurrent treatment with drugs used for bipolar disease: a retrospective chart analysis in human cancer patients","volume":"9","author":"Wadia","year":"2018","journal-title":"Oncotarget."},{"key":"10.1016\/j.critrevonc.2019.102831_bib0590","doi-asserted-by":"crossref","first-page":"28861","DOI":"10.1038\/srep28861","article-title":"Ethoxyquin provides neuroprotection against cisplatin-induced neurotoxicity","volume":"6","author":"Zhu","year":"2016","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.critrevonc.2019.102831_bib0595","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/ana.24004","article-title":"Ethoxyquin prevents chemotherapy-induced neurotoxicity via Hsp90 modulation","volume":"74","author":"Zhu","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.critrevonc.2019.102831_bib0600","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejon.2019.03.002","article-title":"Prevention of chemotherapy-induced peripheral neuropathy with classical massage in breast cancer patients receiving paclitaxel: an assessor-blinded randomized controlled trial","volume":"40","author":"Izgu","year":"2019","journal-title":"Eur. J. Oncol. Nurs."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842819302161?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842819302161?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:30:40Z","timestamp":1760902240000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842819302161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":120,"alternative-id":["S1040842819302161"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2019.102831","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevention of chemotherapy-induced peripheral neuropathy: A review of recent findings","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2019.102831","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102831"}}